Suven Life Science is presenting the data on its lead phase-I clinical candidate SUVN-502 for cognition in Alzheimer's and Schizophrenia at the Rodman & Renshaw 10th Annual Healthcare Conference at New York during 10-12 November 2008. The conference is likely to be attended by top notch investment professionals along with the most innovative companies who present themselves to a targeted audience of decision makers. Venkat Jasti, CEO of Suven will present and discuss the company's strategy, corporate overview and present data.

Suven has six internally discovered therapeutic drug candidates currently in clinical and pre-clinical stage of development targeting conditions such as ADHD, dementia, and depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidates in Alzheimer's disease and Schizophrenia.